n n n ‘.concat(e.i18n.t(“search.voice.recognition_retry”),’n
By Patrick Wingrove
SAN FRANCISCO (Reuters) – Germany’s Bayer will continue its expansion in the United States despite an announcement in November that its promising blood-thinning candidate had failed to demonstrate superiority over a rival drug, Stefan Oelrich, the manufacturer’s chief pharmaceutical officer, said on Monday. .
Bayer’s experimental anticoagulant asundexian could still be a blockbuster if its second trial for stroke prevention reads out positively, Oelrich told Reuters at the JPMorgan health conference in San Francisco.
He added that there are opportunities in the U. S. as well. The U. S. Department of Health and Human Services has been a U. S. researcher for menopausal and cardiovascular symptom relief treatments, which Bayer says has relieved hot flashes and improved sleep in late-stage trials.
“When you take a look at any of the opportunities we’re talking about (in those areas), the praise for innovation in the U. S. is higher than in Europe,” he said.
Bayer announced last November that asundexian had been found to be inferior to Pfizer’s Bristol-Myers Squibb and Eliquis in preventing strokes in high-risk patients, halfway through a late-stage trial called OCEANIC-AF.
The company announced earlier that month that it had announced a trial called OCEANIC-AFINA to test the investigational anticoagulant in patients with traumatic inflammation from the trial who are eligible for treatment with oral anticoagulants due to an increased risk of bleeding.
Oelrich said Bayer still plans to sell the drugs it is developing itself in the country, rather than partner with U.S. companies like it has in the past.
Bayer executive Sebastian Guth told Reuters last March that the drugmaker intended to move away from relying on partners in the U.S. and planned to spend $1 billion on drug research and development in the country in 2023.
Oelrich declined to say Bayer would revise its 5 billion euro forecast for Asundexian after its lawsuit failed.
(Reporting via Patrick Wingrove; editing by Michael Perry)